Other

Gie-cerbn, Centre Europeen De Recherche En Biologie Et En Medecine (gie)

Norbert B Ghyselinck

Pierre H Chambon

Daniel Metzger

Manuel Mark

Val&eacute;rie Dup&eacute;

Emiliana Borrelli

The invention relates to a method for the stable inversion of a DNA fragment upon recombinase-mediated rearrangements using two sets of two incompatible site-specific recombinase targeting sites (SSRTS) in the same order but in reverse orientation flanking the DNA fragment to be inverted. The invention also relates to a method for the stable inversion of the DNA fragment upon rearrangement mediated by a recombinase such as Cre recombinase. The invention also relates to a method for obtaining a transgenic cell of which at least one allele of a DNA sequence of interest is invalidated by a process of conditional deletion and the genome of which has a reporter gene inserted at the place of the DNA fragment deleted by the process of conditional deletion. A method to generate targeting sites to perform site-specific recombination mediated cassette exchange is also provided.

Method for the stable inversion of DNA sequence by site-specific recombination and DNA vectors and transgenic cells thereof

The invention relates to methods for treatment of neurological disease by administering an agent which interacts with a retinoid receptor associated with the neurological disease. The invention is also related to a method of modulating dopamine receptor synthesis by introducing an agent that interacts with a retinoid receptor associated with the dopamine receptor synthesis. The invention is further related to a transgenic animal, e.g., mouse, and mammalian cell line, which is deficient in the normal synthesis of one or more receptors of RAR&agr;, &bgr;, &ggr; and RXR, and cell line thereof.

Use of ligands for treatment of diseases responsive to retinoids

Growing community of inventors

Strasbourg, France

Norbert B Ghyselinck